• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Neurobiogen

Monday, June 03, 2024
CP
CNS/Neurological
NEUROBIOGEN prioritizes its research and development efforts to develop innovative new medicine to treat patients who suffer from degenerative brain diseases and central nervous system diseases. By developing innovative drugs through the efficacy verification and clinical progress of our new drug candidates (KDS2010/Tisolagiline), we will continue our journey to a global company to contribute to human health after all.
Neurobiogen
Company Website: https://www.neurobiogen.com/eng/main/
Lead Product in Development: KDS2010 (Tisolagiline) which is new creative small molecule Drug targeting CNS Diseases like Alzheimer's Disease, Obesity, Parkinson's Disease, Spinalcord injury, Stroke and metabolic inflammatory diseases.

Company HQ City

Seoul

Company HQ State

Seoul

Company HQ Country

Korea, Republic of

CEO/Top Company Official

Sangwook Kim

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS